BMO Capital Positive on Celgene (CELG) REVLIMID Label Expansion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Celgene's (CELG) REVLIMID Receives Expanded FDA Indication for Newly Diagnosed NDMM Patients
February 18, 2015 9:38 AM ESTCelgene (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy.
The approval of REVLIMID as an option for use in all patients with multiple myeloma represents a new paradigm in the management of this disease, said Kenneth Anderson, M.D., Director, Jerome Lipper Multiple Myeloma Center,... More
Celgene (CELG) Confirms No IPRs Filed; BofA/Merrill Lynch Sees Strong Revlimid Patents
February 18, 2015 6:50 AM ESTBofA/Merrill Lynch analyst Ying Huang reiterated a Buy rating and $136 price target on Celgene (NASDAQ: CELG) after the company confirmed that no Inter Partes Reviews (IPRs) have been filed to date on any of its products, including Revlimid and Pomalyst. Management also... More
UPDATE: Canaccord Genuity Starts Celgene (CELG) at Buy
February 18, 2015 6:43 AM EST(Updated - February 18, 2015 9:40 AM EST)
Canaccord Genuity initiated coverage on Celgene (NASDAQ: CELG) with a Buy rating and a price target of $156. Analyst John Newman thinks Revlimid will reach $10 billion in worldwide revenues by 2020. He also noted potential in inflammatory diseases.
"We do not expect generic competition to surface until ~2022-2024, providing substantial cash flows mid-term. Importantly, we expect US FDA approval in front-line multiple myeloma during February... More
